Cas no 84687-43-4 (Astragaloside IV)
Astragaloside IV Chemical and Physical Properties
Names and Identifiers
-
- ASTRAGALOSIDE
- 9,19-CYCLOLANOSTANE-BETA-D-GLUCOPYRANOSIDE
- ASTRAGALOSIDE IV
- Astrasieversianin XIV
- β-D-Glucopyranoside, (3β,6α,16β,20R,24S)-
- Astragaloside Ⅳ
- ASTRAGALOSIDE IV(P)
- ASTRAGALOSIDE IV(RG)
- beta-D-Glucopyranoside, (3beta,6alpha,16beta,20R,24S)-20,24-epoxy-16,25-dihydroxy-3-(beta-D-xylopyranosyloxy)-9,19-cyclolanostan-6-yl
- Astragalus P.E
- Astragalus extract
- Astragalus Polysaccharides
- CH83947
- CH90651
- cyclosieversioside F
- cyclosiversioside F
- KT Astragaloside IV
- 1H,19H-Cyclopropa[9,10]cyclopenta[a]phenanthrene,b-D-glucopyranoside deriv.
- 9,19-Cyclolanostane, b-D-glucopyranoside deriv.
- Astraversianin XIV
- Astragalus Root Extract
- AstragalosideIV
- (2R,3R,4S,5S,6R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R)-14-Hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl
- (2R,3R,4S,5S,6R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R)-14-Hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
- (3β,6α,16β,20R,24S)-20,24-Epoxy-16,25-dihydroxy-3-(β-D-xylopyranosyloxy)-9,19-cyclolanostan-6-yl β-D-glucopyranoside (ACI)
- 1H,19H-Cyclopropa[9,10]cyclopenta[a]phenanthrene, β-D-glucopyranoside deriv. (ZCI)
- 9,19-Cyclolanostane, β-D-glucopyranoside deriv. (ZCI)
- Astragaloside Iv,(S)
- 84687-43-4
- FT-0686574
- 83207-58-3
- NS00018369
- (2R,3R,4S,5S,6R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2S,5R)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.0^{1,3.0^{3,8.0^{12,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
- 2-Hydroxy-1-(5-(1-hydroxy-1-methylethyl)-2-methyltetrahydro-2-furanyl)-3a,6,6,12a-tetramethyl-7-(pentopyranosyloxy)tetradecahydro-1H-cyclopenta[a]cyclopropa[e]phenanthren-5-yl hexopyranoside
- NSC650944
- SY067110
- (2R,3R,4S,5S,6R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.0^{1,3.0^{3,8.0^{12,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
- 16,25-Dihydroxy-3-(pentopyranosyloxy)-20,24-epoxy-9,19-cyclolanostan-6-yl hexopyranoside
- MFCD16036240
- 2-[hydroxy-[5-(1-hydroxy-1-methyl-ethyl)-2-methyl-tetrahydrofuran-2-yl]-tetramethyl-(3,4,5-trihydroxytetrahydropyran-2-yl)oxy-[?]yl]oxy-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol
- DTXSID70868831
- 1ST40060
- C17799
- (2R,3R,4S,5S,6R)-2-[[(1S,3R,8R,9S,11S,12S,14S,15R,16R)-14-Hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
- HMS3885E12
- ASTRAGALOSIDE IV (CONSTITUENT OF ASTRAGALUS) [DSC]
- CHEBI:65457
- Astragaloside IV, United States Pharmacopeia (USP) Reference Standard
- (2R,3R,4S,5S,6R)-2-(((2aR,3R,4S,5aS,5bS,7S,7aR,9S,11aR,12aS)-4-hydroxy-3-((2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethyl-9-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetradecahydro-1H,12H-cyclopenta[a]cyclopropa[e]phenanthren-7-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
- HY-N0431
- 3-O-beta-D-xylopyranosyl-6-O-beta-D-glucopyranosylcycloastragenol
- AS-19402
- ASTRAGALOSIDE IV [USP-RS]
- CHEMBL3121562
- 1J6XA9YCFV
- DTXSID801026063
- Q27133900
- AST-IV
- s3901
- CCG-270470
- Astragaloside IV 95%
- UNII-1J6XA9YCFV
- Astramembrannin I;Astragalin A
- AKOS025311424
- Astragaloside IV, >98.0%
- AS-IV
- SCHEMBL21888259
- (2R,3R,4S,5S,6R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
- Astragaloside IV, European Pharmacopoeia (EP) Reference Standard
- .BETA.-D-GLUCOPYRANOSIDE, (3.BETA.,6.ALPHA.,16.BETA.,20R,24S)-20,24-EPOXY-16,25-DIHYDROXY-3-(.BETA.-D-XYLOPYRANOSYLOXY)-9,19-CYCLOLANOSTAN-6-YL
- Astragaloside A
- GLXC-13550
- A3305
- (2R,3R,4S,5S,6R)-2-(((1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-((2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl)-7,7,12,16-tetramethyl-6-((2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl)oxy-9-pentacyclo(9.7.0.01,3.03,8.012,16)octadecanyl)oxy)-6-(hydroxymethyl)oxane-3,4,5-triol
- AST-IV , AS-IV
- ASTRAGALOSIDE IV (USP-RS)
- ASTRAGALOSIDE IV (CONSTITUENT OF ASTRAGALUS)
- Astragaloside IV
-
- MDL: MFCD16036240
- Inchi: 1S/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20+,21-,22+,23-,24-,25-,26-,27+,28-,29+,30+,31-,32-,33-,34+,37+,38-,39+,40-,41+/m0/s1
- InChI Key: QMNWISYXSJWHRY-YLNUDOOFSA-N
- SMILES: C[C@@]12C[C@H](O)[C@H]([C@]3(CC[C@@H](C(O)(C)C)O3)C)[C@@]1(C)CC[C@@]13C[C@]41CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C(C)(C)[C@@H]4[C@H](C[C@@H]23)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
Computed Properties
- Exact Mass: 784.46100
- Monoisotopic Mass: 784.46090684 g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 9
- Hydrogen Bond Acceptor Count: 14
- Heavy Atom Count: 55
- Rotatable Bond Count: 7
- Complexity: 1460
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 5
- Undefined Atom Stereocenter Count : 16
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 228
- Molecular Weight: 785.0
- XLogP3: 1.3
Experimental Properties
- Color/Form: Powder
- Density: 1.39
- Melting Point: 295-296?°C (lit.)
- Boiling Point: 895.7±65.0 °C at 760 mmHg
- Flash Point: 495.5±34.3 °C
- Refractive Index: 1.62
- PSA: 228.22000
- LogP: 0.72410
Astragaloside IV Security Information
- Signal Word:Warning
- Hazard Statement: H315-H319-H335
- Warning Statement: P261-P305+P351+P338
- Hazardous Material transportation number:NONH for all modes of transport
- WGK Germany:3
- Safety Instruction: S22-S24/25
- Storage Condition:Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
Astragaloside IV Customs Data
- HS CODE:2932999099
- Customs Data:
China Customs Code:
2932999099Overview:
2932999099. Other heterocyclic compounds containing only oxygen heteroatoms. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to
Summary:
2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Astragaloside IV Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| MedChemExpress | HY-N0431-10mM*1mLinDMSO |
Astragaloside IV |
84687-43-4 | ≥98.0% | 10mM*1mLinDMSO |
¥550 | 2023-05-12 | |
| MedChemExpress | HY-N0431-10mg |
Astragaloside IV |
84687-43-4 | 99.93% | 10mg |
¥491 | 2025-04-15 | |
| MedChemExpress | HY-N0431-50mg |
Astragaloside IV |
84687-43-4 | 99.93% | 50mg |
¥1350 | 2025-04-15 | |
| MedChemExpress | HY-N0431-100mg |
Astragaloside IV |
84687-43-4 | 99.93% | 100mg |
¥2400 | 2025-04-15 | |
| S e l l e c k ZHONG GUO | S3901-25mg |
Astragaloside IV |
84687-43-4 | 100.00% | 25mg |
¥795.34 | 2023-09-15 | |
| S e l l e c k ZHONG GUO | S3901-100mg |
Astragaloside IV |
84687-43-4 | 100.00% | 100mg |
¥2350.95 | 2023-09-15 | |
| TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd. | A3305-1G |
Astragaloside IV |
84687-43-4 | >98.0%(HPLC) | 1g |
¥490.00 | 2024-04-15 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | A111275-100mg |
Astragaloside IV |
84687-43-4 | ,≥98% | 100mg |
¥428.90 | 2023-09-04 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | A111275-2.5g |
Astragaloside IV |
84687-43-4 | ,≥98% | 2.5g |
¥4704.90 | 2023-09-04 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | A111275-20mg |
Astragaloside IV |
84687-43-4 | ,≥98% | 20mg |
¥109.90 | 2023-09-04 |
Astragaloside IV Production Method
Production Method 1
1.2 pH 6 - 7
Astragaloside IV Raw materials
Astragaloside IV Preparation Products
Astragaloside IV Suppliers
Astragaloside IV Related Literature
-
Jason Wan Lab Chip, 2020,20, 4528-4538
-
Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
-
Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
-
Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
Additional information on Astragaloside IV
Comprehensive Guide to Astragaloside IV (CAS No. 84687-43-4): Benefits, Applications, and Research Insights
Astragaloside IV (CAS No. 84687-43-4) is a bioactive saponin compound derived from the roots of Astragalus membranaceus, a traditional Chinese herb widely recognized for its immunomodulatory and anti-aging properties. As one of the most studied Astragalus extracts, this compound has garnered significant attention in modern pharmacology, nutraceuticals, and anti-aging research. Its unique molecular structure and multifaceted biological activities make it a focal point for scientists and health enthusiasts alike.
In recent years, the demand for natural bioactive compounds like Astragaloside IV has surged, driven by growing consumer interest in holistic health solutions and longevity science. Search trends reveal frequent queries such as "Astragaloside IV benefits," "how does Astragaloside IV work," and "Astragaloside IV dosage for anti-aging," reflecting its prominence in wellness discussions. This compound’s potential to support cellular health, mitochondrial function, and immune response aligns with contemporary health priorities, including metabolic wellness and stress resilience.
From a biochemical perspective, Astragaloside IV (CAS No. 84687-43-4) belongs to the cycloartane-type triterpene glycoside family, characterized by a four-ring core structure with sugar moieties. This configuration contributes to its high bioavailability and ability to modulate key pathways such as AMPK and mTOR, which are critical for energy metabolism and cellular repair. Research highlights its role in activating telomerase, an enzyme linked to telomere maintenance, further cementing its reputation in age-related research.
The applications of Astragaloside IV extend beyond traditional medicine. In the nutraceutical industry, it is formulated into dietary supplements targeting oxidative stress and inflammatory balance. Clinical studies suggest its efficacy in supporting cardiovascular health by improving endothelial function and reducing arterial stiffness. Additionally, its neuroprotective effects are being explored for conditions like cognitive decline, with preclinical data showing promise in enhancing neuronal survival.
Quality and sourcing are critical for Astragaloside IV efficacy. The compound is typically standardized to ≥98% purity (HPLC) to ensure consistency in research and commercial products. Sustainable extraction methods and plant-derived authentication are increasingly emphasized to meet regulatory and consumer expectations. Analytical techniques like LC-MS and NMR spectroscopy are employed to verify its structural integrity and potency.
Emerging trends also link Astragaloside IV to exercise performance and muscle recovery, with athletes and fitness communities exploring its potential to reduce exercise-induced oxidative damage. Meanwhile, its synergy with other adaptogenic herbs, such as Rhodiola rosea, is under investigation for combined stress-relief formulations. These developments position Astragaloside IV as a versatile ingredient in both preventive health and performance optimization.
In summary, Astragaloside IV (CAS No. 84687-43-4) represents a bridge between traditional wisdom and cutting-edge science. Its multifaceted benefits—spanning anti-aging, immune support, and metabolic health—make it a compelling subject for ongoing research and product innovation. As interest in natural longevity enhancers grows, this compound is poised to remain at the forefront of integrative health solutions.
84687-43-4 (Astragaloside IV) Related Products
- 223924-11-6(b-D-Glucopyranoside, (3b,6a,16b,20R,24S)-20,24-epoxy-16-hydroxy-3,6-bis(b-D-xylopyranosyloxy)-9,19-cyclolanostan-25-yl)
- 101843-83-8(b-D-Xylopyranoside, (3b,6a,16b,20R,24S)-20,24-epoxy-16,25-dihydroxy-6-(b-D-xylopyranosyloxy)-9,19-cyclolanostan-3-yl2-O-(6-deoxy-a-L-mannopyranosyl)-(9CI))
- 135101-62-1(α-L-Mannopyranoside, (3β,6α,16β,20R,24S)-20,24-epoxy-16,25-dihydroxy-3-(β-D-xylopyranosyloxy)-9,19-cyclolanostan-6-yl 6-deoxy-)
- 86764-12-7(Brachyoside B)
- 101843-82-7(b-D-Glucopyranoside, (3b,6a,16b,20R,24S)-3-[[2-O-(6-deoxy-a-L-mannopyranosyl)-b-D-xylopyranosyl]oxy]-20,24-epoxy-16,25-dihydroxy-9,19-cyclolanostan-6-yl)
- 83207-58-3(Astragaloside A)
- 84687-42-3(Astragaloside III)
- 132160-35-1(b-D-Xylopyranoside, (3b,6a,16b,20R,24S)-20,24-epoxy-6,16,25-trihydroxy-9,19-cyclolanostan-3-yl2-O-(6-deoxy-a-L-mannopyranosyl)-(9CI))
- 142735-27-1(β-D-Glucopyranoside, (3β,6α,16β,20R,24S)-20,24-epoxy-25-(β-D-glucopyranosyloxy)-6,16-dihydroxy-9,19-cyclolanostan-3-yl 2-O-D-apio-β-D-furanosyl-)
- 142713-57-3(b-D-Xylopyranoside, (3b,7b,16b,20R,24S)-20,24-epoxy-7,16,25-trihydroxy-9,19-cyclolanostan-3-yl (9CI))